Abstract
Purpose :
Intraocular injection of triamcinolone acetonide (Triesence) is used for treatment for a variety of ophthalmic diseases. A retrospective observational clinical study was performed to determine the different diagnoses being treated with triamcinolone acetonide at a large retina practice.
Methods :
Drawing on internal data from a large retinal specialty practice, Retina Associates of Cleveland, Inc., between 2017 and 2022, patients undergoing intraocular triamcinolone acetonide treatment were collected. The patients were then categorized by diagnosis, to track prevalence of retinal diseases.
Results :
A total of 146 patients receiving triamcinolone acetonide were identified. Data collected showed that 44 patients (30.14%) were being treated for diabetic macular edema, 40 patients (27.40%) were for pseudophakic cystoid macular edema, 23 patients (15.75% ) were for macular/retinal edema, 10 patients (6.85%) were for branch retinal vein occlusion with macular edema, 9 patients (6.16%) were for central retinal vein occlusion with macular edema,5 patients ( 3.42%) were for diabetic retinopathy, 5 patients (3.42%) were for neovascular macular degeneration, 4 patients (2.74%) were for uveitis, 3 patients ( 2.05%) were for epiretinal membrane with macular edema, 1 patient (0.68%) were for serous choroidal detachment, and 1 patient (0.68%) for neovascular glaucoma.
Conclusions :
The study found patients had 11 unique diagnoses that were treated with triamcinolone acetonide. Diabetic macular edema constituted the largest proportion of the treated patient population at 29.93%. Categories with 4 patients or less in them constituted 6.16% of the patient population. Future studies could examine the effects of triamcinolone acetonide on intraocular pressure as well as which diagnosis is most improved with triamcinolone acetonide.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.